Patients with increased urinary frequency and/or imperative urgency and/or urge
incontinence, as can occur in patients with overactive bladder syndrome, for whom Toviaz
was prescribed for treatment of the symptoms.
Patients will complete the OABv8 questionnaire and will need to meet a minimum score in
order to be eligible for the study.
Patients who meet the contraindications in the Toviaz prescribing information (active
ingredient fesoterodine) will be excluded.